Literature DB >> 16020516

Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.

Shao-An Xue1, Liquan Gao, Daniel Hart, Roopinder Gillmore, Waseem Qasim, Adrian Thrasher, Jane Apperley, Boris Engels, Wolfgang Uckert, Emma Morris, Hans Stauss.   

Abstract

Cytotoxic T lymphocytes (CTLs) specific for an HLA-A2-presented peptide epitope of the Wilms tumor antigen-1 (WT1) can selectively kill immature human leukemia progenitor and stem cells in vitro. In this study we have used retroviral gene transfer to introduce a WT1-specific T-cell receptor (TCR) into T lymphocytes obtained from patients with leukemia and from healthy donors. TCR-transduced T cells kill leukemia cells in vitro and display WT1-specific cytokine production. Intravenous injection of TCR-transduced T cells into nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice harboring human leukemia cells resulted in leukemia elimination, whereas transfer of control T cells transduced with an irrelevant TCR was ineffective. The data suggest that adoptive immunotherapy with WT1-TCR gene-modified patient T cells should be considered for the treatment of leukemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020516     DOI: 10.1182/blood-2005-01-0146

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

1.  Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.

Authors:  Amy A Simpson; Fiyaz Mohammed; Mahboob Salim; Amy Tranter; Alan B Rickinson; Hans J Stauss; Paul A H Moss; Neil M Steven; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity.

Authors:  Marleen M van Loenen; Renate de Boer; Avital L Amir; Renate S Hagedoorn; Gerdien L Volbeda; Roelof Willemze; Johannes J van Rood; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 3.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

4.  Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.

Authors:  Michael S Bennett; Aviva Joseph; Hwee L Ng; Harris Goldstein; Otto O Yang
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

5.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

6.  T-cell receptor gene transfer for the treatment of leukemia and other tumors.

Authors:  Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

Review 7.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 8.  Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.

Authors:  Aaron E Foster; Malcolm K Brenner; Gianpietro Dotti
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 9.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

Review 10.  Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.

Authors:  Malcolm K Brenner; Fatma V Okur
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.